Mary Newman

Chief Development Officer

Has more than 30 years of experience in regulatory affairs and research and development within the biotechnology industry, focusing on rare diseases with high unmet medical needs. She most recently served as SVP of Regulatory Affairs at Astellas Gene Therapies (formerly Audentes Therapeutics) and prior to that, she served as SVP, Regulatory Affairs and Quality Assurance, at SARcode Bioscience Inc. and Senior Director of Regulatory Affairs at BioMarin.  She sits on the board of Vedere Bio and is a board advisor to Chameleon Biosciences.